NewsBenzinga누벡티스 파마의 NXP200 BRAF 억제제, 중국 혁신 치료제 지정 획득 누벡티스 파마의 NXP200 BRAF 억제제, 중국 혁신 치료제 지정 획득 Benzinga 2026.09.24 12:05 (GMT+0) Open on Benzinga Other news Wall Street Brunch: SpaceX, Tesla, Meta On The Earnings Card (undefined:SPCX) Fifth Third, Steel Dynamics Earnings Test Bank Trends And Steel Demand UTES Vs. UTG: Why I Prefer The ETF As Rates Rise. (NYSE:UTG) Jefferies Makes a Bold $85 Call on Netflix Stock Earnings Preview: What to Expect From Mosaic’s Report Gartner’s Q3 2026 Earnings: What to Expect
